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GSTP1 gene polymorphismAbstract Background: COPD is a multifactorial disease. It is a widely distributed disease with
high morbidity and mortality, associated with different pathologies. The link between glutathione
S-transferase P-1 (GSTP1) polymorphism and COPD needs to be clariﬁed.
Objectives: To show the relationship between GSTP1 gene polymorphism and pathogenesis of
COPD, and to clarify the role of smoking in GSTP1 gene polymorphism.
Patients and methods: This study carried out on 30 COPD patients met the clinical criteria of
COPD set by GOLD 2013 and 20 healthy controls. Blood was sampled for studying GSTP1 gene
polymorphism by PCR-RFLP.
Results: There was a signiﬁcant difference between group A (COPD smokers) and group B
(COPD non smokers) regarding the presence of non mutant and heterozygous mutation. GSTP1
mutation was signiﬁcantly higher in group C (smoking controls) than group D (non smoking
controls). There was a highly signiﬁcant difference between smoking subjects than non smoking
compared with mutation. There was no signiﬁcant difference in mutation between smokers and
ex-smokers. There was no signiﬁcant difference between studied subjects having heterozygous
mutation and subjects without as regards their spirometry results.
Conclusion: There is a signiﬁcant association between GSTP1 gene polymorphism and the devel-
opment of COPD, and smoking have a role in GSTP1 gene polymorphism. The polymorphism has
no relation to disease severity.
ª 2016 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
COPD is deﬁned as a preventable and treatable disease,
characterized by persistent airﬂow limitation that is usually
progressive and associated with an enhanced chronic
740 T.F. El-Gazzar et al.inﬂammatory response in the airways and the lung to noxious
particles or gases [1].
One of pathogenesis of COPD is oxidant/antioxidant
imbalance. Indeed, it is well known that chronic tobacco
smoking is a major risk factor for the development of COPD,
and a defect in the detoxiﬁcation of reactive species produced
by cigarette smoke may predispose smokers to airﬂow obstruc-
tion and emphysema [2].
Potential explanations for why some cigarette smokers
acquire chronic airways disease but not others include genetic
differences in inﬂammatory and repair processes and/or mod-
ulation of these responses by infections or other environmental
insults suggesting that individual susceptibility or genetic fac-
tors may play a role [3].
Several candidate genes such as a-1-antitrypsin (AAT),
tumor necrosis factor a (TNF-a), heme oxygenase-1 (HMOX),
cytochrome P450, and microsomal epoxide hydrolase
(mEPHX) that could be involved in the development of COPD
were investigated. Among the genes that contribute to xenobi-
otic metabolism and susceptibility to COPD, the glutathione
S-transferase (GST) gene family is one of the most studied in
diverse human populations [2].
GST is a family of enzymes comprising 16 genes in six sub-
families [alpha (GSTA), mu (GSTM), omega (GSTO), pi
(GSTP), theta (GSTT), and zeta (GSTZ)], which is a group
of phase II enzymes that catalyze the glutathione conjugation
of many endogenous and exogenous electrophilic compounds,
such as environmental toxins, and oxidative stress products
[2,4]. The GSTM1, T1 and P1 enzymes are expressed in lung
tissues [5], where the GSTP1 was found to be mainly present
in the respiratory tract [6].
GSTP1 is found in humans with an A (Adenine) to G (Gua-
nine) substitution at exon 5 causing Isoleucine (Ile) to Valine
(Val) replacement at codon number 105 within the active site
of the protein [7].
Aim of the work
The aim of the current study was to evaluate the role of
GSTP1 gene in the pathogenesis of COPD patients and to clar-
ify the role of smoking in GSTP1 gene polymorphism in exon
5.
Patients and methods
This work was carried out on 30 patients with COPD diag-
nosed and classiﬁed according to GOLD 2013 [1], referred to
the Chest Department, Faculty Of Medicine, Menouﬁa
University and Chest hospital of Shebin El Kom. The study
also included 20 healthy controls.
Subjects were divided into:-
Group A: included 15 smoker patients with COPD and
were subdivided into: 10 patients with moderate COPD
and 5 patients with severe COPD.
Group B: included 15 non smoker patients with COPD and
were subdivided into: 11 patients with moderate COPD and
4 patients with severe COPD.
Group C: included 10 healthy smoking volunteers who had
no symptoms or signs of any chest disease and had normal
ventilatory function tests as a control group.Group D: included 10 healthy non smoking volunteers who
had no symptoms or signs of any chest disease and had nor-
mal ventilatory function tests as a control group.
After having a written consent; each patient underwent:
1. Full history taking including smoking history & smoking
index.
2. Full Clinical examination.
3. Chest X-ray (PA & Lat view) and high resolution computed
tomography (HRCT) chest if needed.
4. Electrocardiography (ECG) & Echo if needed.
5. Arterial Blood Gases (ABG).
6. Pulmonary function tests.
Spirometry was done for all subjects. All patients had FEV1/
FVC of less than 70% and post bronchodilator spirometry
was performed after giving the patient a bronchodilator, such
as an inhaled beta-agonist e.g. salbutamol 400 lg) [1].
The following parameters were measured:
(a) Forced expiratory volume in the ﬁrst second (FEV1) pre
and post bronchodilator.
(b) Forced vital capacity (FVC).
(c) FEV1/FVC ratio.
(d) Peak expiratory ﬂow rate (PEFR).
(e) Forced expiratory ﬂow from 25% to 75% (FEF25–75)
of vital capacity.
The classiﬁcation of Severity of Airﬂow Limitation in
COPD patients with FEV1/FVC< 0.70 (Based on Post-
Bronchodilator FEV1) according to GOLD staging system
(GOLD 2013) [1] into:
GOLD 1: Mild FEV1P 80% predicted.
GOLD 2: Moderate 50% 6 FEV1 < 80% predicted.
GOLD 3: Severe 30% 6 FEV1 < 50% predicted.
GOLD 4: Very Severe FEV1 < 30% predicted.
7 blood samples were drawn for studying glutathione
S-transferase P1 gene polymorphism by PCR-RFLP. Blood
collected on EDTA tubes was used for DNA extraction using
gene JET whole blood DNA Mini Kits (Thermo Scientiﬁc,
Sigma) stored at 20 for PCR ampliﬁcation with an initial
denaturation at 95 for 5 min and repeated 40 cycles of denatu-
ration at 95 for 1 min, annealing at 56 for 1 min and extension
at 72 for 1 min followed by a ﬁnal extension at 72 for 5 min
using forward primer (5-GTAGTTTGCCCAAGGTCAAG-
3) and reverse primer (5-AGCCACCTGAGGGGTAAG-3).
PCR product was digested by fast digest AIw26I restriction
enzyme for 2 h at 37.Results
Table 1 shows the distribution of patients and controls regard-
ing their demographic criteria: age, sex, smoking status,
smoking index. The age of the studied patient ranged from
43 to 75 years with mean age and standard deviation of
62.40 ± 9.32 in group A, 59.66 ± 6.33 in group B,
38.30 ± 5.86 in group C and 40.40 ± 7.73 in group D. More-
over, the number of male subjects was higher than females, 36
Table 1 Distribution of the studied groups regarding their demographic criteria.
Groups
A (n= 15) B (n= 15) C (n= 10) D (n= 10)
No % No % No % No %
Age
Mean ± SD 62.40 ± 9.32 59.66 ± 6.33 38.30 ± 5.86 40.40 ± 7.73
Gender
Male 15 100.0 6 40.0 10 100.0 5 50.0
Female 0 0.0 9 60.0 0 0.0 5 50.0
Smoking status
Smoker 4 0 10 0
Ex-smoker 11 0 0 0
Non 0 15 0 10
Table 2 Distribution of the studied groups regarding their Spirometry results.
Spirometry results Groups Fisher’s exact P value
A B C D
(n= 15) (n= 15) (n= 10) (n= 10)
No % No % No % No %
Normal (n= 18) 8 80.0 10 100.0 2.22 0.474
Small airway obstruction (n= 2) 2 20.0 0 0.0
Gold stage
Moderate (n= 21) 10 66.7 11 73.3 0.15 1.0
Severe (n= 9) 5 33.3 4 26.7
Bold values represent number of mutations.
Glutathione S-Transferase P-1 Gene Polymorphism in COPD Patients 741and 14, respectively. Regarding smoking status the number of
current smokers was 14 and ex-smoker was 11, while non
smokers were 25.
Table 2 shows the comparison between the studied groups
regarding their spirometric results, it shows the distribution of
the studied groups regardingGOLD stages of patients in groups
A and B (classiﬁed according to GOLD 2013). There were: 10
(66.7%) smoker patients in group (A) and 11 (73.7%) non-
smoker patients in group (B) had moderate COPD. 5 (33.3%)
smoker patients in group (A) had severe COPD. While from
non-smoker patients in group (B) was 4 (26.7%) with severe
COPD. There was a non signiﬁcant difference between the stud-
ied groups (A) and (B) as regards the GOLD stage
(P-value > 0.05). Regarding the control groups C and D there
were two subjects (20%) of group C (control smokers) having
small airway obstruction and 8 (80%) normal, while those from
non-smoker controls in group (D) were 10 (100%) with normal
pulmonary function tests. There was a non signiﬁcant difference
between the studied groups (C) and (D) as regards to their pul-
monary function tests (P-value > 0.05).
Table 3 shows the distribution of all studied groups regard-
ing mutation of GSTP1 gene polymorphism in each group.
From 15 COPD smoker patients in group (A), 12 (80%) had
heterozygous mutation, from 15 COPD non-smoker patients
in group (B), 5 (33.3%) had heterozygous mutation, from 10
control subjects in group (C), 7 (70%) had heterozygous muta-
tion, while 1 (10%) from 10 control subjects in group (D), a
signiﬁcant difference between groups A and B regarding type
of mutation (P-value > 0.05), highly signiﬁcant differencebetween groups A and D (P-value < 0.01) and a signiﬁcant
difference between groups C and D (P-value > 0.05).
Table 4 shows the distribution of all studied subjects
regarding their smoking status compared with mutation.
Twenty-ﬁve subjects have heterozygous mutation, eleven of
them were smoking, eight were ex-smokers while six were
non smokers. Twenty-ﬁve subjects have normal genotyping
(non mutant), three of them were smoking, three were
ex-smokers while nineteen were non smokers. There was a sig-
niﬁcant difference between subjects having heterozygous muta-
tion and subjects without mutation as regards smoking status
(P-value > 0.05), highly signiﬁcant difference between them as
regards non smoking status (P-value > 0.01) and non signiﬁ-
cant difference as regards ex-smoking status.
Table 5 shows the distribution of all studied groups regard-
ing their spirometry results compared with mutation. There
was no signiﬁcant difference between subjects having heterozy-
gous mutation and subjects without mutation as regards
spirometry results (P-value < 0.05) (see Fig. 1).
Discussion
COPD is a multifactorial disease with possible genetic predis-
position and involvement of various environmental factors.
Among the genes that contribute to xenobiotic metabolism
and susceptibility to COPD, GSTP1 gene is one of the most
studied in diverse human populations [2]. GSTP1 was found
to be mainly present in the respiratory tract and was proposed
to be involved in the development of COPD [6].
Table 4 Distribution of the studied subjects regarding their
smoking status compared with mutation.
Smoking Mutation Z test P value
Non
mutant
(n= 25)
Heterozygous
(n= 25)
No % No %
Smoker 3 12.0 11 41.7 2.05 0.040(S)
Ex-smoker 3 12.0 8 33.3 1.46 0.143
Non 19 76.0 6 25.0 3.32 <0.001(HS)
300 Pb
200 Pb
100 Pb
Figure 1 Shows gel electrophoresis of polymorphism of the
GSTP1 gene. Lane 1 is the molecular marker of 100 bps. Lanes 2,
4, 6, 8 and 9 of 200 pb represents heterozygous mutations of
GSTP1 by substitution of isoleucine (Ile) by valine (Val) at codon
number 105. Lanes 3, 5, 7, 10 and 11 represent a non mutant type
of GSTP1.
Table 3 Distribution of the studied groups regarding their mutation.
Mutation Groups Fisher’s exact P value
A B C D
(n= 15) (n= 15) (n= 10) (n= 10)
No % No % No % No %
Non mutant 3 20.0 10 66.7 3 30.0 9 90.0 F1 = 6.65 P1 = 0.025(S)
F2 = 0.33 P2 = 0.653
F3 = 11.78 P3 < 0.001(HS)
Heterozygous 12 80.0 5 33.3 7 70.0 1 10.0 F4 = 3.23 P4 = 110
F5 = 1.79 P5 = 0.344
F6 = 7.50 P6 = 0.019(S)
F1 = A, B F2 = A, C F3 = A, D F4 = B, C F5 = B, D F6 = C, D.
S = signiﬁcant HS = highly signiﬁcant. Non mutant = mutation is not detected.
Heterozygous = two different alleles of the same gene.
742 T.F. El-Gazzar et al.Smoking alters several genes that can be associated with
health problems for smokers, such as increased risk of COPD
[8].
Only a relatively small proportion of smokers actually
develop airway obstruction. Genetic factors are related to this
susceptibility and include genes regulating the protease–an-
tiprotease and oxidant–antioxidant interactions [9].
Oxidant stress and reactive oxygen species, resulting from
an oxidant/antioxidant imbalance, are believed to play an
important role in the pathogenesis of COPD. Indeed, it is well
known that chronic tobacco smoking is a major risk factor for
the development of COPD, and a defect in the detoxiﬁcation
of reactive species produced by cigarette smoke may predis-
pose smokers to airﬂow obstruction and emphysema [2].Table 5 Distribution of the studied groups regarding their Spirom
Spirometry Mutation
Non mutant (n= 25) H
No % N
Groups (C&D)
Small airway obstruction 0 0.0 2
Normal 12 100.0 6
GOLD stage groups (A&B)
Moderate 11 84.6 1
Severe 2 15.4 7A combination of oxidative attack and changes in antipro-
tease activity could amplify the lung tissue damage in COPD.
This underlines that the interactions between genes as well as
environmental factors may play an important role in the devel-
opment of this pathogenesis [2] .
Lakhdar et al. [2] made a study concerning the relationship
between GSTP1 polymorphism and COPD in a Tunisianetry results compared with mutation.
Fisher’s exact P value
eterozygous (n= 25)
o %
25.0 3.33 0.147
75.0
0 58.8 2.33 0.127
41.2
Glutathione S-Transferase P-1 Gene Polymorphism in COPD Patients 743population and concluded that subjects with GSTP1 Val105
allele are at higher risk of COPD.
So, in the present study, we attempted to analyze the rela-
tionship between GSTP1 gene polymorphism and COPD as
GSTP1 was found to be mainly present in the respiratory tract
and to clarify the role of smoking in GSTP1 gene
polymorphism.
In the current study, the age of the studied patients ranged
from 43 to 75 years old with mean age and standard deviation
of 62.40 ± 9.32 in group A, 59.66 ± 6.33 in group B,
38.30 ± 5.86 in group C and 40.40 ± 7.73 in group D. More-
over, the number of male subjects was higher than females
(Table1). This result comes in agreement with Lakhdar et al.
[2] who explained this result by the fact that the major popu-
lation of COPD patients and chronic smokers are males in
Egypt. Therefore, it is difﬁcult to ﬁnd a balanced set of female
subjects for genotype studies. Secondly, there was a difference
in mean age between cases and controls. In fact, younger con-
trols were more likely to provide a blood sample than older
controls, and were thereby over sampled.
Many studies have reported on the association between
GST gene polymorphisms and pulmonary disorders but with
controversial results [7].
In the present study, on comparing results of GSTP1 gene
polymorphism among the studied COPD patient groups, it
was found that heterozygote mutation was signiﬁcantly higher
in group A (COPD smokers) than in group B (COPD non
smokers). This result comes in accordance with Bentley et al.
[10] who declared that in GSTP1, the heterozygous mutation
due to substitution of Ile amino acid at codon number 105
by Val which causes altered afﬁnity for speciﬁc substrates,
was associated with chronic smoking COPD patients (Table 3).
Similarly, Lakhdar et al. [2] found the Tunisians carrying a
GSTP1 Val105 allele were at higher risk of COPD. In addition,
the meta-analysis completed by Yan et al. [11] suggested that
the GSTP1 105Val/Val genotype was an important genetic
contributor to COPD susceptibility. In contrast, Yim et al.
[12] showed no association between GSTP1 gene polymor-
phism at exon 5 and COPD in Koreans, while Ishii et al.
[13] showed an increased prevalence of homozygous mutation
(similar alleles) in GSTP1 polymorphism at exon 5 in Japanese
COPD patients.
Regarding (Table 4) of the current study, the number of
detected GSTP1 mutations was signiﬁcantly higher in smoking
patients than those not smoking or quit smoking. Out of
twenty-ﬁve heterozygous mutations detected, eleven subjects
were smoking (41.7%), six were not smoking (25%) and eight
were ex-smokers (33.3%).
This result comes in accordance with Spira [14] who stated
that some people who smoke respond differently at a genetic
level to a cigarette smoke. These people may be at a heightened
risk of developing COPD because genes that normally protect
lung cells against environmental toxins are altered, including
some genes linked to COPD. Moreover, Zuntar et al. [7]
reported that there were no signiﬁcant differences between
healthy smokers and COPD-smokers.
Regarding (Table 5), the current study showed no signiﬁ-
cant difference between studied subjects having heterozygous
mutation and subjects without as regards spirometry results.
This result comes in accordance with the International
Journal of COPD., [15] a study search that identiﬁed 104 pub-
lications reporting a total of 130 genes and 48 intergenicregions studied in 20,288 individuals including GSTP1 exon
5 polymorphism. This great study declared that none of the
studied genes was signiﬁcantly associated with forced expira-
tory volume in one second (FEV1) or FEV/forced vital capac-
ity (FVC) ratio after correction for multiple testing.
Moreover, Rodriguez et al. [16] declared that no signiﬁcant
association was observed in different genotypes of the GSTP1
with lung function in the group of patients with COPD. They
reported that the GSTP1 genotypes studied did not seem to
inﬂuence the severity of lung function impairment in patients
with COPD.
However, in a large study designed by He et al. [17] involv-
ing 1098 individuals with different degrees of lung function
impairment, the results demonstrated a signiﬁcant association
of mutation with rapid decline in lung function in smokers
with mild to moderate airﬂow obstruction.
Conclusion
From the present study we concluded that there is a relation-
ship between GSTP1 gene polymorphism and development
of COPD. Smoking has a role in GSTP1 gene polymorphism.
GSTP1 gene polymorphism in COPD patients has no relation
to the GOLD stage. Further works using a larger population
and studying more candidate genes taking in account the
gene-environment interaction remains necessary in order to
elucidate the genetic pathogenesis of COPD.Conﬂict of interest
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